LGND MEXC RealStocks
Own real LGND shares through MEXC's regulated brokerage partner.
Suitable for long-term holding.
- Own the actual shares
- Receive dividends and voting rights
- Buy fractional shares starting at $1
Last updated: 2026-11-16 05:14:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Ligand Pharmaceuticals Inc. (LGND) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $309.04, with a market capitalization of $6.18B and a P/E ratio of 120.02. Over the past 52 weeks, its price has ranged from $175.89 to $326.63. This page covers its latest market performance, valuation, price trends and company information.
$6.18B | |
$313.98 | |
$317.79 | |
$308.64 | |
$316.27 | |
99.36K | |
226.64K | |
120.02 | |
$326.63 | |
$175.89 | |
-- | |
-- |
Ligand Pharmaceuticals Inc. (LGND) last closed at $309.04 as of 2026-11-14 01:00:00, down 2.37% ($7.48) from the previous close of $316.27.
During the latest regular trading session, LGND traded between $308.64 and $317.79, with a volume of 99.36K shares. The closing price was near the lower end and near the upper end of its 52-week range.
Over the past seven days, Ligand Pharmaceuticals Inc. (LGND) moved from $299.00 to $309.04, representing a gain of 3.36% ($10.04).
The stock traded between $297.63 and $325.89 during the period. The latest price is near the middle of the 7-day range, indicating moderate upward.
The average daily volume was 172.06 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 88.3%
LGND is currently trading at $309.04, placing it 88.3% of the way from its 52-week low of $175.89 to its 52-week high of $326.63. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 47 |
| Exchange | NASDAQ |
| Company Website |
View the latest dividend and stock split events for Ligand Pharmaceuticals Inc.
Dividend | |
|---|---|
| Ex-Dividend Date | Jul 2, 2010 |
| Payment Date | Jul 1, 2010 |
| Dividend Per Share | $0.07632878 |
Eligible investors can buy real shares of Ligand Pharmaceuticals Inc. (LGND) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.
Stock prices and market data on this page, including price changes and market status, are provided by Massive and other third-party news and data platforms. Market data may be delayed and may differ from prices on other platforms or the prices at which trades are executed on MEXC. MEXC does not guarantee the accuracy, completeness, or timeliness of third-party data. MEXC offers trading products related to LGND, including Stocks, Tokenized Stocks, and Stock Futures.
The stock price information displayed on this page is provided for reference purposes only and may be delayed or differ from real-time market data. Prices, charts, and related metrics do not constitute investment advice and should not be relied upon for trading or investment decisions. MEXC is not responsible for any losses incurred based on the stock price information provided on this page. Please refer to official market sources or consult licensed financial professionals before making any investment decisions.
Estimate the value between LGND shares and USD.
LGND Shares to USD
1.00 LGND shares = 309.039 USD
Calculations are estimates based on the latest available price and are for reference only.